These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 4983851

  • 1. Nondialyzable urinary hydroxyproline as an index of bone collagen formation.
    Haddad JG, Couranz S, Avioli LV.
    J Clin Endocrinol Metab; 1970 Mar; 30(3):282-7. PubMed ID: 4983851
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Chromatographic analysis of urinary amino acids in Paget's disease. II : clinical study].
    Roques CF, Mazières B, Amigues H, Fournie A, Arlet J, Ruffié R.
    Rev Rhum Mal Osteoartic; 1976 Apr; 43(4):255-8. PubMed ID: 1273475
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of Paget's disease with salmon calcitonin].
    Manderlier T, Fuss M, Brauman J, Orloff S, Bergans A, Corvilain J.
    Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):59-66. PubMed ID: 319520
    [No Abstract] [Full Text] [Related]

  • 9. Human calcitonin in the treatment of Paget's bone disease.
    Woodhouse NJ, Bordier P, Fisher M, Joplin GF, Reiner M, Kalu DN, Foster GV, MacIntyre I.
    Lancet; 1971 Jun 05; 1(7710):1139-43. PubMed ID: 4102856
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Newer agents in treating Paget's disease of bone.
    Goldfield EB.
    Geriatrics; 1974 Dec 05; 29(12):61-9. PubMed ID: 4279196
    [No Abstract] [Full Text] [Related]

  • 12. The origin of urinary hydroxylysyl glycosides in Paget's disease of bone and in primary hyperparathyroidism.
    Askenasi R, De Backer M, Devos A.
    Calcif Tissue Res; 1976 Nov 24; 22(1):35-40. PubMed ID: 1000341
    [Abstract] [Full Text] [Related]

  • 13. Biochemical markers of bone turnover in Paget's disease.
    Russell RG, Beard DJ, Cameron EC, Douglas DL, Forrest AR, Guilland-Cumming D, Paterson AD, Poser J, Preston CJ, Milford-Ward A, Woodhead S, Kanis JA.
    Metab Bone Dis Relat Res; 1981 Nov 24; 3(4-5):255-62. PubMed ID: 6220191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia.
    Bell NH, Avery S, Johnston CC.
    J Clin Endocrinol Metab; 1970 Sep 24; 31(3):283-90. PubMed ID: 4916538
    [No Abstract] [Full Text] [Related]

  • 16. Acute effects of calcitonin on bone formation in man.
    Krane SM, Harris ED, Singer FR, Potts JT.
    Metabolism; 1973 Jan 24; 22(1):51-8. PubMed ID: 4734129
    [No Abstract] [Full Text] [Related]

  • 17. The urinary excretion of inorganic pyrophosphate in hyperparathyroidism, hyperthyroidism, Paget's disease and other disorders of bone metabolism.
    Russell RG, Hodgkinson A.
    Clin Sci; 1969 Jun 24; 36(3):435-43. PubMed ID: 4307562
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [A method of fractionating urinary peptides containing hydroxyproline].
    Borel JP, Caranjot JM, Jayle MF.
    Clin Chim Acta; 1967 Jun 24; 16(3):409-16. PubMed ID: 6035187
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.